X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Terclara (terbinafine) is a topical squalene monooxygenase inhibitor antifungal drug candidate, which is launched in Sweden for the treatment of onychomycosis.
Lead Product(s): Terbinafine
Therapeutic Area: Infections and Infectious Diseases Product Name: Terclara
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
MOB-015 (terbinafine) is an in-house developed topical formulation, which is investigated for the treatment of onychomycosis and Topline results are expected in January 2025.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 (terbinafine hydrochloride) in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Padagis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2022
Details:
The agreement with Allderma complements the existing licensing agreement for MOB-015 in Europe. Allderma is responsible for marketing, distribution and sales in Sweden, Denmark and Norway, while Moberg Pharma is responsible for the manufacture and delivery of the product.
Lead Product(s): Terbinafine
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allderma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 08, 2021
Details:
MOB-015 is our next-generation nail fungus treatment targeting both over-the-counter (OTC) and prescription markets around the world. The company's timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in 2023.
Lead Product(s): Terbinafine
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate the current Convertible Loan Agreement.
Lead Product(s): Terbinafine
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Financing November 06, 2020
Details:
MOB-015's superior mycological cure (percentage of patients who were fungus free) has now been demonstrated in two pivotal studies, providing further support for the company's target to make MOB-015 the future market leader in onychomycosis.
Lead Product(s): Terbinafine
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
MOB-015 (topical terbinafine) met the primary endpoint in the European Phase 3 study including 452 onychomycosis patients, showing non-inferiority versus topical ciclopirox. Mycological cure was achieved in 84 percent of patients.
Lead Product(s): Terbinafine
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
The agreement with N&G enables Moberg Pharma to pursue this potential and conduct an additional clinical study, depending on the outcome of the EU study expected at the end of Q2 2020.
Lead Product(s): Terbinafine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nice & Green S.A
Deal Size: $21.2 million Upfront Cash: Undisclosed
Deal Type: Financing March 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
